CLAIMS

1. An orodispersible solid pharmaceutical dosage unit having a weight between 30 and 1,000 mg, said dosage unit consisting of:
   - 0.1-25 wt.% of estetrol particles containing at least 80 wt.% of an estetrol component selected from estetrol, estetrol esters and combinations thereof; and
   - 75-99.9 wt.% of one or more pharmaceutically acceptable ingredients;

   the solid dosage unit comprising at least 100 µg of the estetrol component;
   wherein the solid dosage unit can be obtained by a process comprising:
   - providing estetrol particles containing at least 80 wt.% of the estetrol component and having a volume median diameter of 2 µm to 50 µm;
   - mixing the estetrol particles with one or more granulation excipients to produce a granulation mixture;
   - mixing the granulation mixture with a granulation liquid to produce estetrol-containing granules, said granulation liquid containing at least 60 wt.% of liquid solvent;
   - removing liquid solvent from the estetrol-containing granules to produce dry estetrol-containing granules;
   - optionally mixing the dry granules with one or more tabletting excipients; and
   - forming the dry granules or the mixture of the dry granules and the one or more tabletting excipients into a solid dosage unit.

2. Dosage unit according to claim 1, wherein the dosage unit has a weight between 40 and 500 mg.

3. Dosage unit according to claim 1 or 2, wherein the dosage unit contains of 0.5-25 wt.% of the estetrol component.

4. Dosage unit according to any one of the preceding claims, wherein the dosage unit contains 0.3-100 mg of the estetrol component.

5. Dosage unit according to any one of the preceding claims, wherein the estetrol component is estetrol.

6. Dosage unit according to any one of the preceding claims, wherein the estetrol particles have a volume median diameter of 3-35 μm.

7. Dosage unit according to any one of the preceding claims, wherein the dosage unit contains 50-99.9 wt.% of water-soluble carbohydrate selected from maltose, fructose, sucrose, lactose, glucose, galactose, trehalose, xylitol, sorbitol, erythritol, maltitol, mannitol, isomalt and combinations thereof.

8. Dosage unit according to claim 7, wherein the dosage unit contains at least 20 wt.% mannitol.

9. Dosage unit according to any one of the preceding claims, wherein the dosage unit contains 0.1-20 wt.% of a disintegrating agent selected from modified starches, crosslinked polyvinylpyrrolidone, crosslinked carmellose and combinations thereof.

10. A solid dosage unit according to any one of the preceding claims for use in medical treatment or for use in female hormone replacement therapy, said use comprising sublingual, buccal or sublabial administration of the dosage unit.

11. Solid dosage unit for the use according to claim 10, said use comprising once daily administration during a period of at least 1 week.

12. A method of female contraception, said method comprising sublingual, buccal or sublabial administration of a dosage unit according to any one of claims 1-9.

13. Method according to claim 12, said method comprising once daily administration during a period of at least 1 week.

14. A process of preparing a solid dosage unit according to any one of the preceding claims, said process comprising the steps of:

- providing estetrol particles containing at least 80 wt.% of an estetrol component selected from estetrol, estetrol esters and combinations thereof and having a volume median diameter of 2 μm to 50 μm;
- mixing the estetrol particles with one or more granulation excipients to produce a granulation mixture;
- mixing the granulation mixture with a granulation liquid to produce estetrol-containing granules, said granulation liquid containing at least 60 wt.% of liquid solvent;
- removing liquid solvent from the estetrol-containing granules to produce dry estetrol-containing granules;
- optionally mixing the dry granules with one or more tabletting excipients; and
- forming the dry granules or the mixture of the dry granules and the one or more tabletting excipients into a solid dosage unit.

15. Process according to claim 14, wherein the estetrol particles have a volume median diameter of 3-35 μm.

16. Process according to claim 14 or 15, wherein the granulation mixture contains 0.1-20 wt.% of a disintegrating agent selected from modified starches, croslinked PVP, crosslinked carmellose and combinations thereof.

17. Process according to any one of claims 14-16, wherein the granulation mixture is produced by combining the estetrol particles with the one or more granulation excipients in a weight ratio that is in the range of 1:4 to 1:1,000.

18. Process according to any one claims 14-17, wherein the estetrol-containing granules are produced by mixing the granulation mixture with the granulation liquid in a weight ratio that is in the range of 0.5:1 to 20:1.

19. Process according to any one of claims 14-18, wherein the estetrol-containing granules are produced by mixing the granulation mixture with the granulation liquid in a high shear granulator, a low shear granulator of a fluidized bed granulator.

20. Process according to any one of claims 14-19, wherein the granulation liquid contains at least 60 wt.% of polar solvent selected from water, methanol, ethanol, iso-propanol, acetone and combinations thereof.

21. Process according to claim 20, wherein the granulation liquid contains at least 60 wt.% of polar solvents selected from water, ethanol and combinations thereof.

22. Process according to claim 20 or 21, wherein the polar solvent contains at least 80 wt.% water.

23. Process according to any one of claims 14-22, wherein the granulation liquid contains 02-50 wt.% of binder, said binder being selected from cellulose derivatives, starch and starch derivatives, polyvinyl alcohol, polyvinylpyrrolidone, agar, gelatin, guar gum, gum Arabic, alginate, polyethylene glyvol, glucose, sucrose, sorbitol and combinations thereof.

24. Process according to claim 23, wherein the binder is selected from cellulose derivatives, pregelatinized starch, polyvinylpyrrolidone and combinations therof.

25. Process according to claim 23 or 24, wherein the cellulose derivatives are selected from hydroxypropyl cellulose, hydroxyethyl cellulose, hydroxymethyl cellulose, hydroxypropylmethylcellulose, methylcellulose, ethylcellulose, carboxymethyl cellulose and combinations thereof.

26. Process according to any one of claims 14-25, wherein the dry estetrol-containing granules have a volume median diameter in the range of 100-4,000 μm.

27. Process according to any one of claims 14-26, wherein the one or more tabletting excipients include lactose, mannitol, xylitol, microcrystalline cellulose, starch, croscarmellose sodium, polyvinyl pyrrolidone and combinations thereof.

28. Process according to any one of claims 14-27, wherein the solid dosage unit is formed by direct compression or compression moulding.